Abstract: One aspect of the present invention provides a method comprising: manufacturing a sodium ion secondary cell having an anode and a cathode, the anode comprising a negative electrode active material comprising disordered carbon on an anode substrate, and the cathode comprising a comprising a nickel-containing sodium oxide positive electrode active material on a cathode substrate; and in a cycling phase, charging the cell to a first voltage; wherein the ratio of the mass of the negative electrode active material to the mass of the positive electrode active material is greater than 0.37 and is less than 1.2.

Abstract: A method of operating a rechargeable sodium ion cell, wherein the cell comprises an anode material which is a disordered carbon and a nickel-containing sodium oxide cathode material comprises: in a formation charge phase, charging the cell to a first voltage at which sodium is irreversibly liberated from the cathode material; and in a subsequent charge-discharge cycle, charging the cell to a second voltage lower than the first voltage. The voltage to which the cell is charged in the formation charge phase may be selected such that the amount of sodium irreversibly liberated from the cathode material in the formation charge phase substantially equals the amount of sodium deposited in a surface electrolyte layer on the anode in the formation charge phase.

Abstract: The present invention provides a method of producing 2,3,3,3-tetrafluoropropene (HFO-1234yf), wherein the method comprises two or more reaction steps, at least one of said reaction steps comprising the production of 1,3,3,3-tetrafluoropropene (HFO-1234ze) and/or one or more HFO-1234ze precursors from one or more HFO-1234yf precursors, wherein at least a portion of the HFO-1234ze is recovered.

Abstract: The present invention relates to aryl pyrazoles, and pharmaceutically acceptable salts thereof. The aryl pyrazoles of the present invention are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorders. The present invention also relates to pharmaceutical compositions comprising the aryl pyrazoles of the present invention, methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein A1, A2, L1 and B are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

Abstract: The present invention relates to compounds of formula (I): wherein R1 to R3, A, X and n are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorder. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

Abstract: An embodiment in accordance with the present invention provides an implanted catheter and an external device that the patient uses to inject a therapeutic into the implanted tube. The implanted catheter can be equipped with a fixation mechanism that secures the catheter in place and eases physician insertion and removal. The fixation mechanism can include shape memory arms having silicone tips or can be a second catheter branch configured to hold the device in the user's sinus cavity. The catheter can also include numerous exit holes to prevent obstruction and deliver the therapeutic. An interface between the implanted catheter and the external device is incorporated, to ensure a reliable seal for medication passage. A method and device for delivery of the catheter to the correct position can also be included.

Abstract: A photovoltaic cell comprises a membrane electrode assembly obtainable by the in situ polymerization between two electrodes of one or more monomers to form a polymer, and then infusing an activating agent into the polymer, wherein the activating agent enables the membrane electrode assembly to function as a photovoltaic cell.

Abstract: The present invention relates to compounds of formula (I): wherein R1 to R3, A, X and n are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorder. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

Abstract: The present invention relates to aryl pyrazoles, and pharmaceutically acceptable salts thereof. The aryl pyrazoles of the present invention are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorders. The present invention also relates to pharmaceutical compositions comprising the aryl pyrazoles of the present invention, methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

Abstract: Disclosed is a compound of formula (I). Wherein R1, R2Ar and Cy are as defined herein, or a pharmaceutically acceptable salt thereof. Also disclosed are pharmaceutical compositions of the compound of formula (I), methods of making the compounds of formula I, and methods of using the compounds of formula (I) to treat a disorder associated with activation of CCR10.

Abstract: A flexible MEA comprises an integral assembly of electrode, catalyst and ionomeric membrane material.

Abstract: Disclosed are compounds and compositions of the formula I as described herein which are inhibitors of MMP-13. Also disclosed are methods of using and making compounds of the formula I.

Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein A1, A2, L1 and B are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

Abstract: Disclosed are compounds and compositions of the formula (I) as described herein which are inhibitors of MMP-13. Also disclosed are methods of using and making compounds of the formula (I).

Abstract: Instant messaging (IM) is provided and translated between parties that speak different languages, such as between a foreign language speaker and an entity. One or more converters may convert the foreign language speaker's speech to IM text in the speaker's language, which may then be translated into a language used by the entity. The foreign language speaker may provide IM text instead of speaking, and this IM text in the foreign language may be translated into IM text in a language used by the entity. The translated IM text or the speech converted from the translated IM text may then be provided as text, or may be converted to speech and provided as speech, to the entity, or a representative associated with the entity.

Abstract: The present invention relates to compounds of formula (I): wherein R1 to R3, A, X and n are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorder. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

Abstract: This invention relates to a compound of formula (I) and the pharmaceutically acceptable salts thereof wherein R1, R2, R4. Ar and Het are as defined herein. The invention also relates to methods of using the compound of formula (I) to treat a diseases and disorders that are mediated or sustained through the activity of CCR10.

Abstract: A photovoltaic cell comprises a membrane electrode assembly obtainable by the in situ polymerisation between two electrodes of one or more monomers to form a polymer, and then infusing an activating agent into the polymer, wherein the activating agent enables the membrane electrode assembly to function as a photovoltaic cell.